Who is sponsoring NCT05702619?

NCT05702619 is sponsored by The Christie NHS Foundation Trust.

What drugs are being tested in NCT05702619?

Interventions in NCT05702619: Optional non-IMP pimonidazole, CT-guided Bone Biopsy, TRUS-guided Targeted Transperineal Prostate Biopsy, Radical Prostatectomy, Whole-body MRI, Prostate MRI scans, Baseline bloods - for germline testing, Baseline bloods for CTCs and ct DNA taken at same time as baseline bloods in Arm 1, Post-pimonidazole bloods for CTCs and ctDNA.

What condition does NCT05702619 study?

NCT05702619 studies Prostate Cancer, Hypoxia.

Is NCT05702619 still recruiting?

NCT05702619 is currently status unknown. Last updated 27 January 2023.

Last reviewed 2023-01-27 · How we verify

NCT05702619: HYPROGEN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hypoxia-driven Prostate Cancer Genomics (HYPROGEN)

Status unknown Last updated 27 January 2023

What this trial tests

trial testing Optional non-IMP pimonidazole in Prostate Cancer in 60 participants. Status unknown.

Timeline

3 October 2021

Primary endpoint
30 June 2023

30 June 2023

Quick facts

Lead sponsor	The Christie NHS Foundation Trust
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	60
Start date	3 October 2021
Primary completion	30 June 2023
Estimated completion	30 June 2023
Sites	1 location across United Kingdom

Drugs / interventions tested

Optional non-IMP pimonidazole — full drug profile →
CT-guided Bone Biopsy
TRUS-guided Targeted Transperineal Prostate Biopsy
Radical Prostatectomy
Whole-body MRI
Prostate MRI scans
Baseline bloods - for germline testing
Baseline bloods for CTCs and ct DNA taken at same time as baseline bloods in Arm 1
Post-pimonidazole bloods for CTCs and ctDNA

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →
Hypoxia — all drugs for Hypoxia →

Sponsor

The Christie NHS Foundation Trust

Who can join

18 and older, male only, with Prostate Cancer or Hypoxia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Due to the rapid growth, tumour demand for oxygen is often higher than what can be delivered by the newly forming blood vessels. Tumour adaption to this imbalanced oxygen supply and demand (hypoxia) is associated with poor prognosis and genetic changes (genomic instability) that allow it to become more resistant to chemo- and radiotherapy. Patients with hypoxic tumours therefore die earlier. Limited information is available on hypoxia in newly diagnosed prostate cancer, especially to what degree hypoxia in the prostate tumour is associated with the presence of metastases to bones. The Hyprogen trial is a prospective, non-randomised, exploratory biopsy and imaging biomarker study recruiting 60 patients with prostate cancer to better establish the role of hypoxia in prostate cancer cells evolution and early metastatic spread.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

From Hypoxia to Bone: Reprogramming the Prostate Cancer Metastatic Cascade.
Santos M, Koushyar S, Dart DA, Uysal-Onganer P. · · 2025 · cited 1× · PMID 40806577 · DOI 10.3390/ijms26157452

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other The Christie NHS Foundation Trust trials

Trials by the same sponsor.

NCT07183267 — Using Red Light Therapy to Ease Skin Side Effects and Mouth Side Effects, in Children and Young People Aged 0 to 16 Year · NA · not yet recruiting
NCT07268339 — A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calme · Phase 3 · not yet recruiting
NCT06965101 — To Determine Whether it is Feasible to Treat Patients Requiring Urgent Radiotherapy Diagnosed With Metastatic Cord Compr · NA · recruiting
NCT05903430 — A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION) · recruiting
NCT07202260 — Pragmatic Analysis of Complex Radiotherapy Cases In Cancer of the Lung · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05702619 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Christie NHS Foundation Trust
Last refreshed: 27 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05702619.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing